Characterization of a new solvate of risedronate

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 863-873

  Brüning, Jürgen ^a   Petereit, Anna Christine ^a   Alig, Edith ^a   Bolte, Michael ^a   Dressman, Jennifer B ^a   Schmidt, Martin U ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Bisphosphonates; Crystal structure; Crystallization; Dissolution; Hydrates solvates; Osteoporosis; Polymorphism; Risedronate; X ray diffractometry

Indexed keywords

ACETIC ACID; BUFFER; PEPSIN A; RISEDRONIC ACID; WATER;

ARTICLE; CHEMICAL COMPOSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; PH; SOLVATE;

EID: 79251578638     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22327     Document Type: Article

References (39)

1. Cawthon PM, Litwack SL, Barrett-Conor E, Canley J, Lewis C, Fink H, Orwoll E, Cummings SR. 2006. IOF World Congress on Osteoporosis, P115SA, s24.
2. Tucker KL, Morita K, Qiao N, Hannan MT, Cuppels LA, Kiel DP. 2006. Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham osteoporosis study. Am J Clin Nutr 84(4): 936-942.
3. Fleisch H. 1998. Bisphosphonates: Mechanisms of action. Endocrional Rev 19(1): 80-100.
4. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. 2000. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (12 Suppl.): 2961-2978.
5. Rodan GA. 1998. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38(1): 375-388.
6. Menschutkin N. 1865. Ueber die Einwirkung des Chloracetyls auf phosphorige Säure. Ann Chem Pharma 133: 317-320.
7. Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD. 1969. Diphosphonates in the treatment of myositis ossificans. Lancet 2: 845.
8. von Baeyer H, Hofmann KA. 1897. Acetodiphosphorige Säure. Beitr Dtsch Chem Ges 30: 1973-1978.
9. Fleisch H, Russell RGG, Bisaz S, Casey PA, Mühlbauer RC. 1968. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 2 (Suppl.): 10-10A.
10. Fleisch H, Russell RGG, Straumann F. 1966. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212(5065): 901-903.
11. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 13(4): 581-589.
12. von Beek E, Löwik C, Van Der Pluijm G, Papapoulus S. 1999. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14(5): 722-729.
13. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reska AA. 1999. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci 96(1): 133-138.
14. Sato M, Gasser W. 1990. Effects of bisphosphonates in isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5(1): 31-40.
15. Ito M, Amizuka N, Nakajima T, Ozawa H. 1999. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 25(4): 447-452.
16. Diez-Perez A. 2002. Bisphosphonates. Maturitas 43 (Suppl. 1): 19-26.
17. Sweetman S. 2005. Martindale: The complete drug reference. 34st ed. Chicago: Pharmaceutical Press.
18. Ogura Y, Gonsho A, Cyong JC, Orimo H. 2004. Clinical trial of risedronate in Japanese volunteers: A study on the effects of timing of dosing on absorption. J Bone Miner Metab 22(2): 120-126.
19. Dansereau RJ, Burgio DE. 2006. Dosage form of risedronate. US patent application. US2006/0110452 A1.
20. Janner M, Muhlbauer RC, Fleisch H. 1991. Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif Tissue Int 49(4): 280-283.
21. van Hoogdalem EJ, Wackwitz AT, de Boer AG, Breimer DD. 1989. 3-Amino-1-hydroxypropylidene-1, 1-diphosphonate (APD): A novel enhancer of rectal cefoxitin absorption in rats. J Pharm Pharmacol 41(5): 339-341.
22. Shrewsbury RP, Wurster DE, Dittert LW. 1985. Dose-dependent effect of calcium and magnesium etidronate on salicylic acid absorption in the rat. J Pharm Pharmacol 37(6): 440-442.
23. Monkkonen J, Ylitalo P. 1990. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration. Eur J Drug Metab Pharmacokinet 15(3): 239-243.
24. Illum L. 1996. Nasal delivery. The use of animal models to predict performance in man. J Drug Target 3(6): 427-442.
25. Ezra A, Golomb G. 2000. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42(3): 175-195.
26. Brüning J, Alig E, Nachtsheim B, Bolte M, Schmidt MU. 2007. Essigsäure-Solvate von Risedronat, Polymorph hiervon, deren Herstellung und Verwendung sowie pharmazeutische Zusammensetzung, enthaltend diese. German patent application. DE 102007030370 A1.
27. Paulekuhn GS, Dressman JB, Saal C. 2007. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. J Med Chem 50(26): 6665-6672.
28. Cazer FD, Perry GE, Billings DM, Redman-Furey NL. 2001. Selective crystallization of 3-pyridyl-1-hydroxy-ethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate. European patent application. EP 1252170 A2.
29. Aronhime J, Lifshitz-Liron R, Kovalevski-Ishai E, Lidor-Hadas R. 2003. Novel polymorphs and pseudopoly-morphs of risedronate sodium. Canadian patent. CA 2480764 A1.
30. STOE & Cie 1988. STADI/P-Fast powder diffraction system. STOE & Cie, Darmstadt, Germany.
31. Redman-Furey NL, Dicks M, Bigalow-Kern A, Cambron RT, Lubey G, Lester C, Vaughn D. 2005. Structural and analytical characterization of three hydrates and an anhydrate form. J Pharm Sci 94(4): 893-911.
32. Gossman WL, Wilson SR, Oldfield E. 2003. Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures. Acta Cryst C59(2): m33-m36.
33. STOE & Cie 2000. IPDSII-single crystal diffractometer. STOE & Cie, Darmstadt, Germany.
34. STOE & Cie 2001. X-AREA & X-step, programs for data collection, cell refinement and cell reduction. STOE & Cie, Darmstadt, Germany.
35. Sheldrick GM. 1997. SHELXS97 and SHELXL97. University of Göttingen, Göttingen, Germany.
36. The united states pharmacopeia (USPaNF). 2008. USP-NF 31st ed., U.S.P.C. Inc., Rockville, MD, USA.
37. Jantradid E, Janssen N, Reppas C, Dressman JB. 2008. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 25(7): 1663-1676.
38. Spek AL. 2003. Single crystal structure validation with the program PLATON. J Appl Cryst 36(1): 7-13.
39. Nguyen T, Kim KJ. 2008. Kinetic study on hemipenta hydrate risedronate monosodium in batch crystallization by cooling mode. Int J Pharm 364(1):1-8.